Develops oncology drug candidates and protein-based tests to identify cancer patients whose tumors may respond to treatment.
10-K for FY2025, filed Mar 19, 2026
8-K, filed Nov 6, 2026
On November 6, 2026, Acrivon Therapeutics, Inc., a Delaware corporation (the “Company”), announced that it has entered into an asset…View ↗
A dual kinase candidate enters clinical testing
The older report described separate preclinical programs targeting these kinases; the latest report describes a dual inhibitor as a clinical-stage asset.
10-K for FY2022, filed Mar 28, 2023 10-K for FY2025, filed Mar 19, 2026We also have two preclinical drug programs designed to take advantage of our AP3 platform and the ability to predict tumor sensitivity…View ↗
We are also leveraging our proprietary Generative Phosphoproteomics AP3 precision medicine platform for streamlined drug discovery through…View ↗
Broader treatment approach for serous tumors
The older report planned biomarker-guided treatment across ovarian, endometrial and bladder cancers; the latest report adds serous endometrial cancer arms that do not require biopsy or biomarker stratification.
10-K for FY2022, filed Mar 28, 2023 10-K for FY2025, filed Mar 19, 2026Based on these results, we have initiated a Phase 2 clinical trial where we are treating patients with all three tumor types…View ↗
While Lilly had explored ACR-368 in many solid tumor types in the above-mentioned studies, they never tested endometrial cancer, or EC.…View ↗
Competes with Boundless Bio, Sierra Oncology, Sentinel Oncology, Astrazeneca/Merck, Zentalis, Debiopharm, Impact Therapeutics, Shouya Holdings, Aprea, BioCity Biopharma, Wigen Biomedicine Technology, HUYA Biomedicines, Bristol Myers Squibb, Repare Therapeutics, Qilu Pharma, Evariste, and Schrödinger
10-K for FY2025, filed Mar 19, 2026At present, we do not believe we face competition from segments of the pharmaceutical, biotechnology and other related markets that pursue…View ↗
Loading...